Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults
{{output}}
Objective: A thorough QT study of favipiravir, a novel antiviral agent, was conducted using a randomized, doubleblind, 4-group, 4-period crossover, placebo-and positive-controlled (open-label moxifloxacin) design. ... ...
